Female Bladder Cancer Array
Improved Risk Stratification of Haematuria Patients
Identify Individuals at Greatest Risk of Bladder Cancer
There is an urgent critical need for additional evidence-based risk stratification models to inform triage and/or management decisions for patients presenting with haematuria. Current diagnostic methods such as cystoscopy and cytology are invasive, carry risks for the patient and have several limitations.
In addition, existing biomarkers lack specificity and may fail to differentiate between all possible causes of haematuria. Utilising patented biochip technology, the female bladder cancer array will allow accurate risk stratification of female patients presenting with haematuria. Bladder cancer is the 8th most common cancer in females, although more common in males mortality is twice as high in females highlighting the need for alternative diagnostic methods.
Interleukin-12 p70 (IL12p70) is a disulphide linked heterodimeric cytokine which regulates inflammation by linking innate and adaptive immune responses and potent inducer of antitumor immunity.
Interleukin-13 (IL-13) is an immunoregulatory cytokine which plays an important role in carcinogenesis through affecting tumor immunosurveillance. IL-13 in the bladder cancer patients suggests that this cytokine is involved in progression in bladder cancer patients.
Midkine is a member of a family of heparin-binding growth factors, which was reported to have an important role in angiogenesis and is associated with bladder cancer progression.
Bladder Tumor Antigen (BTA) known as human complement factor H-related protein to aids in management of patients with bladder cancer.
The Evidence Investigator
Meet the Evidence Investigator
Developed for use on the Evidence Investigator, a semi-automated benchtop immunoassay analyser.
Want to know more?
Contact us or visit our Investigator Webpage